Brain-derived neurotrophic factor in adolescents with recurrent headache, correction and prevention of its disorders

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To assess the level of brain-derived neurotrophic factor (BDNF) in the blood plasma of adolescents with recurrent headache (RH).

Materials and methods. 440 people (boys and girls) aged 12–18 years were examined, including 240 adolescents with RH (main group) and 200 without RH (control group). The content of BDNF in blood plasma (ng/ml) was determined on the Multiscan FC apparatus (Finland) by the Quantikine® ELISA method using the R&D systems® reagent kit (USA). The obtained data were processed in the Statistiсa 12 program.

Results. A lower content of BDNF in the blood plasma of adolescents with RGB was revealed. A large number of individuals with a reduced level of BDNF among adolescents with RH was established. Significant differences were found in the percentage of adolescents with different levels of plasma BDNF concentration depending on the frequency of RH episodes. Approaches to the correction and prevention of BDNF level disorders in the body of adolescents with RH are described in detail. The feasibility of using both drug and non-drug methods is substantiated.

Conclusion. Given the significant role of BDNF in modulating neuroplastic processes, the decrease in its level that we have identified can probably be regarded as a metabolic marker of the presence of neurodegenerative processes in the brain tissue of adolescents with RH. This assumption can be confirmed by further studies.

Full Text

Restricted Access

About the authors

Yu. R. Kostyuchenko

Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences, Scientific Research Institute of Medical Problems of the North

Author for correspondence.
Email: potupchik_tatyana@mail.ru
ORCID iD: 0000-0001-6233-6472
SPIN-code: 7480-2064
Russian Federation, Krasnoyarsk

T. V. Potupchik

Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia

Email: potupchik_tatyana@mail.ru
ORCID iD: 0000-0003-1133-4447
SPIN-code: 8353-3513

Candidate of Medical Sciences

Russian Federation, Krasnoyarsk

Yu. V. Zykova

Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia

Email: potupchik_tatyana@mail.ru
ORCID iD: 0000-0001-7819-1845
Russian Federation, Krasnoyarsk

L. S. Evert

Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences, Scientific Research Institute of Medical Problems of the North; N.F. Katanov Khakass State University, Ministry of Education and Science of Russia, Medical Institute

Email: potupchik_tatyana@mail.ru
ORCID iD: 0000-0003-0665-7428
SPIN-code: 4099-8973

MD

Russian Federation, Krasnoyarsk; Abakan

E. M. Shenderovich

N.F. Gamaleya Research Institute of Epidemiology and Microbiology, Ministry of Health of Russia

Email: potupchik_tatyana@mail.ru
ORCID iD: 0009-0003-3382-1411
Russian Federation, Moscow

References

  1. Живкович М., Ермолаева Е.В., Соболева А.В. и др. Нейротрофический фактор мозга BDNF: новые данные, функции и вопросы. Гены и Клетки. 2024; 19 (1): 61–84 [Zhivkovich M., Ermolaeva E.V., Soboleva A.V. et al. Brain neurotrophic factor BDNF: new data, functions and issues. Genes and Cells. 2024; 19 (1): 61–84 (in Russ.)]. doi: 10.17816/gc623163
  2. Barreda Tomás F.J., Turko P., Heilmann H. et al. BDNF Expression in Cortical GABAergic Interneurons. Int J Mol Sci. 2020; 21 (5): 1567. doi: 10.3390/ijms21051567
  3. Giacobbo L.B., Doorduin J., Klein H.C. et al. Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation. Mol Neurobiol. 2019; 56 (5): 3295–312. doi: 10.1007/s12035-018-1283-6
  4. Holmuratova B., Rashidova N., Khalimova K. et al. The role of BDNF in the clinical course of primary headaches. Cephalalgia Reports. 2023; 6. doi: 10.1177/25158163231190292
  5. Заваденко Н.Н., Шипилова Е.М., Нестеровский Ю.Е. и др. Головная боль напряжения – болезнь детей, подростков и взрослых. Терапия. 2021; 7 (5): 66–76 [Zavadenko N.N., Shipilova E.M., Nesterovskiy Yu.E. et al. Tension headache is a disease of children, adolescents, and adults. Therapy. 2021; 7 (5): 66–76 (in Russian)]. doi: 10.18565/therapy.2021.5.66-76
  6. Тян К.В., Калинский П.П. Значение мозгового нейротрофического фактора (BDNF) в патогенезе хронической головной боли напряжения. Российский журнал боли. 2020; 18 (2): 5–8 [Tyan K.V., Kalinskiy P.P. The importance of cerebral neurotrophic factor (BDNF) in the pathogenesis of chronic tension headache. The Russian Journal of Pain. 2020; 18 (2): 5–8 (in Russ.)]. doi: 10.17116/pain2020180215
  7. Thakkar B., Acevedo E.O. BDNF as a biomarker for neuropathic pain: Consideration of mechanisms of action and associated measurement challenges. Brain and Behavior. 2023; 13 (3): e2903. doi: 10.1002/brb3.2903
  8. Ziplow J. The Psychiatric Comorbidities of Migraine in Children and Adolescents. Curr Pain Headache Rep. 2021; 25: 69. doi: 10.1007/s11916-021-00983-y
  9. Koute V., Michalopoulou A., Siokas V. et al. Val66Met polymorphism is associated with decreased likelihood for pediatric headache and migraine. Neurol Res. 2021; 43 (9): 715–23. doi: 10.1080/01616412.2021.1922181
  10. Mazzitelli M., Kiritoshi T., Presto P. et al. BDNF Signaling and Pain Modulation. Cells. 2025; 14: 476. doi: 10.3390/cells14070476
  11. Björkholm C., Monteggia L.M. BDNF – a key transducer of antidepressant effects. Neuropharmacology. 2016; 102: 72–9. doi: 10.1016/j.neuropharm.2015.10.034
  12. Bondar N.P., Merkulova T.I. Brain-derived neurotrophic factor and early-life stress: Multifaceted interplay. J Biosci. 2016; 41 (4): 751–8. doi: 10.1007/s12038-016-9648-3
  13. Walsh J.J., Tschakovsky M.E. Exercise and circulating BDNF: Mechanisms of release and implications for the design of exercise interventions. Appl Physiol Nutr Metab. 2018; 43 (11): 1095–104. doi: 10.1139/apnm-2018-0192
  14. Loprinzi P.D. Does brain-derived neurotrophic factor mediate the effects of exercise on memory? Phys Sports Med. 2019; 47 (4): 395–405. doi: 10.1080/00913847.2019.1610255
  15. Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ «STATISTICA». М.: Медиа Сфера, 2002 [Rebrova O.Y. Statistical analysis of medical data. Application of the STATISTICA software package. Moscow: Media Sphere, 2002 (in Russ.)].
  16. Потупчик Т.В., Веселова О.Ф., Эверт Л.С. Ноотропные препараты при нарушениях когнитивных функций у детей. Врач. 2016; 4: 75–8 [Potupchik T., Veselova O., Evert L. Evaluation of the efficiency of using nootropics to treat cognitive dysfunctions in children. Vrach. 2016; 4: 75–8 (in Russ.)].
  17. Lorca C., Mulet M., Arévalo-Caro C. et al. Plant-derived nootropics and human cognition: A systematic review. Crit Rev Food Sci Nutr. 2022; 63 (22): 5521–45. doi: 10.1080/10408398.2021.2021137
  18. Baird J.F., Gaughan M.E., Saffer H.M. et al. The effect of energy-matched exercise intensity on brain-derived neurotrophic factor and motor learning. Neurobiol Learn Mem. 2018; 156: 33–44. doi: 10.1016/j.nlm.2018.10.008
  19. Miao Z., Wang Y., Sun Z. The Relationships Between Stress, Mental Disorders, and Epigenetic Regulation of BDNF. Int J Mol Sci. 2020; 21 (4): 1375. doi: 10.3390/ijms21041375
  20. Loh N.R., Whitehouse W.P., Howells R. What is new in migraine management in children and young people? Arch Dis Child. 2022; 107: 1067–72. doi: 10.1136/archdischild-2021-322373
  21. Cortel-LeBlanc M.A., Orr S.L., Dunn M. et al. Managing and preventing migraine in the emergency department: a review. Ann Emerg Med. 2023; 82 (6): 732–51. doi: 10.1016/j.annemergmed.2023.05.024
  22. Saitoh K., Furihata R., Kaneko Y. et al. Association of serum BDNF levels and the BDNF Val66Met polymorphism with the sleep pattern in healthy young adults. PloS One. 2018; 13 (8): e0201994. doi: 10.1371/journal.pone.0201994
  23. Торшин И.Ю., Громова О.А. О неврологических функциях и синергизме витаминов B1, B6 и B12. Российский журнал боли. 2022; 20 (1): 56–64 [Torshin I.Yu., Gromova O.A. Neurological functions and synergism of vitamins B1, B6 and B12. Russian Journal of Pain. 2022; 20 (1): 56–64 (in Russ.)]. doi: 10.17116/pain20222001156
  24. Seyedi M., Gholami F., Samadi M. et al. The Effect of Vitamin D₃ Supplementation on Serum BDNF, Dopamine, and Serotonin in Children with Attention-Deficit/Hyperactivity Disorder. CNS Neurol Disord Drug Targets. 2019; 18 (6): 496–501. doi: 10.2174/1871527318666190703103709
  25. Шувалова Е.П., Смирнов, В.В., Костюкевич В.И. Возможности применения ноотропов для улучшения нейротрофической поддержки головного мозга. Российские медицинские вести. 2023; 28 (3): 10–5 [Shuvalova E.P., Smirnov, V.V., Kostyukevich V.I. Possibilities of using nootropics to improve the neurotrophic support of the brain. Russian medical news. 2023; 28 (3): 10–5 (in Russ.)].
  26. Липатова Л.В., Серебряная Н.Б., Сивакова Н.А. и др. Способ лечения заболеваний, ассоциированных со сниженной продукцией BDNF. Патент RU2555344C2 от 07.10. 2015 [Lipatova L.V., Serebryanskaya N.B., Sivakova N.A. et al. A method of treating diseases associated with reduced BDNF production. Patent RU2555344C2 dated 07.10. 2015 (in Russ.)].
  27. Abiri B., Vafa M. Effects of vitamin D and/or magnesium supplementation on mood, serum levels of BDNF, inflammatory biomarkers, and SIRT1 in obese women: a study protocol for a double-blind, randomized, placebo-controlled trial. Trials. 2020; 21: 225. doi: 10.1186/s13063-020-4122-9
  28. Dolotov O.V., Karpenko E.A., Inozemtseva L.S. et al. Semax, an analog of ACTH(4–10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006; 1117 (1): 54–60. doi: 10.1016/j.brainres.2006.07.108
  29. Фирстова Ю.Ю., Долотов О.В., Кондрахин Е.А. и др. Влияние ноотропных препаратов на уровень BDNF в гиппокампе и коре мозга мышей с различной эффективностью исследовательского поведения. Экспериментальная и клиническая фармакология. 2009; 72 (6): 3–6 [Firstova Y.Yu., Dolotov O.V., Kondrakhin E.A. et al. Effects of Nootropic Drugs on Hippocampal and Cortical BDNF Levels in Mice with Different Exploratory Behavior Efficacy. Experimental and Clinical Pharmacology. 2009; 72 (6): 3–6 (in Russ.)]. doi: 10.30906/0869-2092-2009-72-6-3-6
  30. Shadrina M., Kolomin T., Agapova T. et al. Comparison of the temporary dynamics of Ngf and Bdnf gene expression in rat hippocampus, frontal cortex, and retina under Semax action. J Mol Neurosci. 2010; 41 (1): 30–5. doi: 10.1007/s12031-009-9270-z
  31. Новикова Д.А., Арсеньева Е.Н. Влияние комплексной терапии на содержание нейротрофических факторов у новорожденных с церебральной ишемией. Российский педиатрический журнал. 2012; 5: 9–13 [Novikova D.A., Arsenieva E.N. Effect of combined therapy for the maintenance of neurotrophic factors in newborn infants with cerebral ischemia. Russian Pediatric Journal. 2012; 5: 9–13 (in Russ.)].
  32. Гусев Е.И., Мартынов, М.Ю., Костенко Е.В. и др. Влияние применения семакса и времени начала реабилитационных мероприятий на динамику содержания в крови нейротрофического фактора головного мозга, восстановление двигательных нарушений и функциональной активности у больных, перенесших ишемический инсульт. Журнал неврологии и психиатрии. 2018; 3 (2): 64–70 [Gusev E.I., Martynov, M.Y., Kostenko E.V. et al. Influence of Semax application and time of rehabilitation measures beginning on the dynamics of brain neurotrophic factor blood content, recovery of motor disorders and functional activity in patients with ischemic stroke. Journal of Neurology and Psychiatry. 2018; 3 (2): 64–70 (in Russ.)].
  33. Ашмарии И.П., Левицкая Н.Г., Каменский А.А. и др. Семакс – новое лекарственное средство для коррекции кровообращения мозга, гипоксических состояний и повышения умственной работоспособности. Фарматека. 1997; 4: 32–3 [Ashmarie I.P., Levitskaya N.G., Kamensky A.A. et al. Semax – a new drug for correction of cerebral blood circulation, hypoxic conditions and increase of mental performance. Farmateka. 1997; 4: 32–3 (in Russ.)].
  34. Абрамова М.Ф. Определение значения венозных церебральных нарушений у детей в клинической практике с возможностью обоснованной терапии. Лечащий врач. 2017; 5: 23–9 [Abramova M.F. Definition of significance of venous cerebral disorders in children in clinical practice, with possibility of grounded therapy. Lechaschi Vrach. 2017; 5: 23-9 (in Russ.)].
  35. Mojtabavi H., Saghazadeh A., van den Heuvel L. et al. Peripheral blood levels of brain-derived neurotrophic factor in patients with post-traumatic stress disorder (PTSD): A systematic review and meta-analysis. PLoS One. 2020; 15 (11): e0241928. doi: 10.1371/journal.pone.0241928
  36. Hajhashemy Z., Golpour-Hamedani S., Eshaghian N. et al. Practical supplements for prevention and management of migraine attacks: a narrative review. Front Nutr. 2024; 11: 1433390. doi: 10.3389/FNUT.2024.1433390
  37. Nasirdinova N.A., Karimova G.L. Headache in children and adolescents. Ethiopian International Journal of Multidisciplinary Research. 2024; 11 (01): 332–42.
  38. Самсонова Т.В. Применение семакса в восстановительном лечении детей первого года жизни с перинатальным гипоксически-ишемическим поражением головного мозга. Российский вестник перинатологии и педиатрии. 2013; 5: 109–14 [Samsonova T.V. Use of Semax in the rehabilitation treatment of infants with perinatal hypoxic-ischemic encephalopathy during the first year of life. Ros Vestn Perinatol Pediat. 2013; 5: 109–14 (in Russ.)].
  39. Студеникин В.М. Пептидный препарат для интраназального введения в психоневрологии и педиатрии. Поликлиника. 2016; 1: 1–6 [Studenikin V.M. The peptide drug for intranasal administration in pediatrics and psychoneurology. Poliklinika. 2016; 1: 1–6 (in Russ.)].

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Distribution of adolescents of the compared groups by plasma BDNF levels

Download (42KB)
Indexing metadata
3. Fig. 2. Plasma BDNF levels in groups of adolescents with and without rare, frequent episodes of recurrent headaches

Download (50KB)
Indexing metadata

Copyright (c) 2025 Russkiy Vrach Publishing House